The majority of the human genome remains undrugged, representing 96% of all human gene targets. Of the roughly 20 thousand proteins encoded in the human genome, only a little over 750 are targeted by FDA-approved small molecule drugs. About 2-3 thousand have a small molecule or a biologic under development.
About 4 thousand genes have experimental evidence linking them to human disease, but may not yet have enough structural data for traditional drug design. These proteins are ready for de novo drug discovery to be immediately explored with our AI technology, representing a potential 4-fold increase beyond the total number of available FDA-approved drugs existing today.
The remaining human gene targets represent novel biology, and contain the most challenging and most promising future targets for pharma and human health. Our AI technology has demonstrated success unlocking new drug targets with little to no structure or activity data, opening up new avenues for drug discovery. Today, over 14 thousand targets can be pursued to start a project with Atomwise.
Future drugs are hidden in an enormously vast chemical space. We solve the most challenging targets by running the largest scale drug screens in history to fully explore this space.
With AtomNet® technology we can screen billions of synthesizable molecules against biological targets in days. Once we find hits, we ship synthesized compounds to our partners within weeks for in-lab screening.
Thousands of Compounds
Millions of Compounds
We solve the hardest problems in computer-aided drug design, delivering hits even when there is little-to-no structural data for a target. AtomNet® screens make-on-demand molecules so that our AI results won't send our partners down a synthesis rabbit hole. Our partners receive compounds to test in their lab 2-3 weeks after we complete a virtual screen. We have a history of success, delivering at least one hit validated in laboratory experiments 74% of the time, keeping our partners ahead of their competition.
With a 74% overall success rate with the most challenging targets across hundreds of projects spanning every class of protein and disease area.
AtomNet® technology uses the world's largest screening library of over 16B+ molecules - and is covered by 19 issued patents, and yielding 12 pending patent applications to date.
Our experienced team includes 80% PhD's including structural biology, medicinal chemistry, engineering and drug development.